Tadalafil (Generic) and Levothyroxine Interaction

Why This Combination Raises Questions

Patients on daily low-dose tadalafil (2.5 or 5 mg) for BPH or erectile dysfunction who also take levothyroxine for hypothyroidism frequently ask whether the two drugs interact. The concern stems from levothyroxine's well-known sensitivity to co-administered substances. Calcium, iron, proton-pump inhibitors, and even coffee can reduce T4 absorption by 25 to 40% [1]. That reputation makes patients cautious about adding any new medication.

Tadalafil, however, does not share the physicochemical properties that cause those absorption problems. It is a lipophilic phosphodiesterase type 5 (PDE5) inhibitor absorbed in the upper GI tract without requiring an acidic environment for dissolution [2]. No chelation, no pH alteration, no mucosal coating effect. The pharmacological profiles of these two drugs simply do not collide.

Mechanism Analysis: CYP Enzymes, Transporters, and Pharmacodynamics

Tadalafil undergoes extensive hepatic metabolism primarily through cytochrome P450 3A4 (CYP3A4), with a minor contribution from CYP2C9 [2]. Levothyroxine is not metabolized by CYP enzymes at all. T4 is deiodinated to T3 by type 1 and type 2 deiodinase enzymes in the liver, kidneys, and peripheral tissues [3]. These are selenium-dependent enzymes completely separate from the cytochrome P450 system.

On the transporter side, tadalafil does not inhibit or induce P-glycoprotein (P-gp) at therapeutic concentrations [2]. Levothyroxine absorption involves organic anion transporting polypeptides (OATPs), specifically OATP1A2 and OATP4A1 in the intestinal epithelium [4]. There is no overlap.

From a pharmacodynamic standpoint, PDE5 inhibition increases cyclic GMP in vascular smooth muscle, producing vasodilation. Thyroid hormone acts on nuclear receptors to regulate basal metabolic rate, cardiac output, and thermogenesis. These pathways do not converge in a way that produces additive toxicity or antagonism.

One theoretical consideration deserves mention. Hyperthyroidism increases hepatic blood flow and can modestly accelerate CYP3A4 activity [5]. A patient whose levothyroxine dose produces supraphysiologic T4 levels could theoretically clear tadalafil slightly faster. The clinical significance is negligible because tadalafil's therapeutic window is wide (2.5 to 20 mg), and no case reports document treatment failure from this mechanism.

Drug Interaction Database Ratings

Major drug interaction databases classify this combination consistently. The Lexicomp database does not list any interaction between tadalafil and levothyroxine. Micromedex returns no interaction record. The FDA's Adverse Event Reporting System (FAERS) contains no signal linking co-prescription of these agents to unexpected outcomes [6].

This is not an absence-of-evidence situation where the combination simply has not been studied. It reflects the pharmacological reality that two drugs with non-overlapping metabolic pathways, different absorption mechanisms, and unrelated pharmacodynamic targets do not interact. The classification is "no known interaction" rather than "interaction of unknown significance."

The Real Issue: Levothyroxine Absorption Timing

The practical question is not whether tadalafil interferes with levothyroxine, but whether the patient is following proper levothyroxine administration technique regardless of other medications. The American Thyroid Association (ATA) recommends taking levothyroxine 60 minutes before breakfast or 3 hours after the last meal on an empty stomach with water only [7].

Tadalafil taken as needed (10 or 20 mg before sexual activity) poses no timing conflict because it is typically dosed in the evening. Daily tadalafil (2.5 or 5 mg) is taken at the same time each day, usually in the morning. If a patient takes both in the morning, the recommendation is simple: take levothyroxine first with water, wait 30 to 60 minutes, then take tadalafil with or without food.

This is not because tadalafil interferes with T4 absorption. It is because the glass of water and the empty stomach are what levothyroxine requires, and any co-administered tablet (even a vitamin without minerals) can slightly delay gastric emptying.

Dr. Victor Bernet, past president of the American Thyroid Association, has stated: "The key principle with levothyroxine is consistency. If a patient takes it the same way every day, on an empty stomach, the TSH will reflect that routine and the dose can be adjusted accordingly" [7].

When Thyroid Status Affects Tadalafil Efficacy

A more clinically relevant question is whether untreated or undertreated hypothyroidism affects erectile function independently of any drug interaction. The answer is yes. Hypothyroidism is associated with erectile dysfunction in 60 to 80% of affected men, and the mechanism involves both reduced nitric oxide synthesis and altered sex hormone binding globulin (SHBG) levels [8].

A 2008 study by Carani et al. published in the Journal of Clinical Endocrinology and Metabolism (N=48) demonstrated that normalizing TSH restored erectile function in 60% of hypothyroid men without any PDE5 inhibitor [8]. This means that optimizing levothyroxine dose may reduce the need for tadalafil entirely, or improve its efficacy when used.

Conversely, subclinical hyperthyroidism from levothyroxine over-replacement can cause premature ejaculation and anxiety-related sexual dysfunction [8]. The clinical takeaway: TSH should be in the reference range (0.4 to 4.0 mIU/L, ideally 0.5 to 2.5 mIU/L for symptom optimization) before attributing erectile dysfunction solely to vascular causes.

Monitoring Parameters for Patients on Both Drugs

No additional laboratory monitoring is required solely because a patient takes both tadalafil and levothyroxine. Standard monitoring applies to each drug independently:

Levothyroxine: TSH checked 6 to 8 weeks after any dose change, then every 6 to 12 months once stable [7]. Free T4 if TSH is discordant with symptoms.

Tadalafil: No routine labs required for the drug itself. However, the FDA label recommends checking blood pressure before initiating tadalafil in patients on antihypertensives [2]. Hypothyroidism can cause diastolic hypertension, so confirming adequate thyroid replacement before starting tadalafil is reasonable clinical practice.

If a patient reports reduced tadalafil efficacy after a levothyroxine dose reduction, the appropriate response is to check TSH and free testosterone, not to assume a drug interaction.

Drugs That Actually Interact With Each Medication

Understanding what does interact with these drugs clarifies why they do not interact with each other.

Levothyroxine absorption reducers (must be separated by 4 hours): calcium carbonate, ferrous sulfate, aluminum hydroxide antacids, sucralfate, cholestyramine, sevelamer, and lanthanum [1]. These work by chelation or binding in the GI lumen. Tadalafil does neither.

Levothyroxine metabolism accelerators: rifampin, phenytoin, carbamazepine, and phenobarbital induce hepatic glucuronosyltransferases and increase T4 clearance [3]. Tadalafil does not induce these enzymes.

Tadalafil level increasers: CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) raise tadalafil AUC by 107 to 312% [2]. The FDA label recommends reducing tadalafil to 2.5 mg daily with strong CYP3A4 inhibitors. Levothyroxine has no CYP3A4 inhibitory activity.

Tadalafil level reducers: CYP3A4 inducers (rifampin, phenytoin) decrease tadalafil exposure. Rifampin reduced tadalafil AUC by 88% in a pharmacokinetic study [2]. Levothyroxine does not induce CYP3A4.

Tadalafil pharmacodynamic interactions: nitrates (absolute contraindication due to severe hypotension), alpha-blockers (start tadalafil at 2.5 mg if on tamsulosin), and potent antihypertensives [2]. Levothyroxine is not a vasodilator and does not affect blood pressure through nitric oxide pathways.

Special Populations

Elderly patients (over 65): No dose adjustment for either drug based on age alone, but renal function should guide tadalafil dosing. CrCl <30 mL/min requires tadalafil dose reduction to 5 mg maximum for as-needed use [2]. Levothyroxine requirements decrease with age; over-replacement risk is higher.

Patients with cardiac disease: Both hypothyroidism and PDE5 inhibitor use intersect with cardiovascular risk. The Princeton III Consensus recommends exercise stress testing before prescribing PDE5 inhibitors to men with intermediate cardiac risk [9]. Uncontrolled hypothyroidism elevates LDL cholesterol and homocysteine, increasing cardiac risk independently.

Women on levothyroxine considering tadalafil for Raynaud's or pulmonary hypertension: The same absence of interaction applies. Tadalafil 40 mg (as Adcirca) for pulmonary arterial hypertension does not interact with levothyroxine through any identified mechanism [10].

Dose-Adjustment Recommendations

No dose adjustment of either medication is needed when co-prescribed.

The Endocrine Society and the ATA do not list PDE5 inhibitors among agents requiring levothyroxine dose modification [7]. The FDA-approved tadalafil label does not mention thyroid medications in its drug interaction section [2].

If TSH rises unexpectedly in a patient stable on levothyroxine, investigate the standard causes: new calcium or iron supplement, switch to a different levothyroxine manufacturer (bioequivalence varies by 12.5% between generic formulations per FDA standards), dietary changes increasing soy or fiber intake, or medication non-adherence [1]. Do not attribute TSH changes to tadalafil without evidence.

Patient Counseling Points

For patients asking their prescriber about this combination, the practical guidance is direct:

1. Take levothyroxine on an empty stomach with a full glass of water, at least 30 to 60 minutes before food or other medications
2. Tadalafil can be taken at any time relative to levothyroxine without pharmacokinetic concern
3. If using daily tadalafil and morning levothyroxine, simply take levothyroxine first and wait your usual interval before eating or taking other pills
4. Report any new symptoms of hyperthyroidism (palpitations, tremor, heat intolerance) or hypothyroidism (fatigue, cold intolerance, constipation) at follow-up, as these warrant TSH testing regardless of tadalafil use
5. Do not stop either medication based on interaction concerns without consulting your prescriber

The European Association of Urology 2024 guidelines on male sexual dysfunction confirm that PDE5 inhibitors can be prescribed alongside thyroid replacement therapy without specific precautions [11].

Hypothyroidism, Erectile Dysfunction, and Treatment Sequencing

A clinical pearl worth emphasizing: men newly diagnosed with both hypothyroidism and erectile dysfunction should have thyroid replacement optimized first. The Corona et al. meta-analysis (2012, 11 studies, N=3,269) found that subclinical hypothyroidism doubled the odds of erectile dysfunction (OR 2.08 to 95% CI 1.42 to 3.05) [12].

Starting levothyroxine and waiting 8 to 12 weeks for TSH normalization before initiating tadalafil is cost-effective and may eliminate the need for a PDE5 inhibitor entirely. If erectile dysfunction persists after TSH reaches target range and free testosterone is normal (>300 ng/dL), tadalafil 5 mg daily is a reasonable next step with expected response rates of 70 to 80% based on pooled data from the LVHB (Lilly-ICOS) registration trials [2].